GSK’s ex-vaccine, pharma lead jumps ship to run G1 Therapeutics
Nearly two months after GlaxoSmithKline’s U.S. pharma and vaccine head left the Big Pharma in the middle of it making a pandemic shot, Jack Bailey has penned a deal to lead cancer biotech G1 Therapeutics.